RAPT Therapeutics Presents Positive Phase 2 CSU Data and Outlines Ozureprubart's Path in Food Allergy and Urticaria
RAPT has more than doubled off its 52-week low of $5.665 on light trading volume (0.4× avg).
Summary
RAPT Therapeutics presented at the J.P. Morgan Healthcare Conference, detailing positive Phase 2 data for Ozureprubart in Chronic Spontaneous Urticaria and outlining its clinical development strategy for food allergies and future milestones.
Key Events · Product Development and Regulatory · RAPT
-
Positive Phase 2 CSU Data
Ozureprubart demonstrated comparable efficacy and safety to omalizumab in Chronic Spontaneous Urticaria, with sustained efficacy for 16 weeks, supporting a best-in-class profile.
-
Food Allergy Trial Progress
The company initiated a Phase 2b clinical trial for Ozureprubart in food allergy, with topline data anticipated in the first half of 2027.
-
Strategic Milestones Outlined
Key upcoming milestones include initiating a Phase 3 CSU trial in 2H 2026 and further asthma development, positioning Ozureprubart for significant market opportunities.
-
Strong Financial Runway
RAPT Therapeutics is well-funded, with cash projected to last through mid-2028, covering multiple critical clinical milestones.
Analysis · RAPT · Life Sciences
The presentation provides a comprehensive update on Ozureprubart (RPT904), highlighting its potential as a next-generation anti-IgE antibody with advantages over existing treatments like omalizumab. Positive Phase 2 data in Chronic Spontaneous Urticaria (CSU) supports its best-in-class profile, with plans for Phase 3 initiation in 2H 2026. The company also initiated a Phase 2b trial for food allergies, with data expected in 1H 2027, targeting multi-billion dollar markets. The projected cash runway through mid-2028, covering these key milestones, provides financial stability. These updates offer significant clarity on the company's pipeline progress and commercial strategy, reinforcing the investment thesis.
At the time of this filing, RAPT was trading at $34.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $943.8M. The 52-week trading range was $5.67 to $42.39. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.